BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36072584)

  • 1. Identification of
    Zhou R; Peng N; Li W
    Front Immunol; 2022; 13():975503. PubMed ID: 36072584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
    Li C; Wan Z; Deng Q; Li Z; Wang Y
    Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
    Lu H; Wu J; Liang L; Wang X; Cai H
    Front Immunol; 2022; 13():803355. PubMed ID: 35154117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment.
    Ma J; Hu J; Zhao L; Wu Z; Li R; Deng W
    BMC Urol; 2024 Jan; 24(1):6. PubMed ID: 38172792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer.
    Huang Z; Yan Y; Wang T; Wang Z; Cai J; Cao X; Yang C; Zhang F; Wu G; Shen B
    J Transl Med; 2022 Jul; 20(1):315. PubMed ID: 35836227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration.
    Huang C; Li Y; Ling Q; Wei C; Fang B; Mao X; Yang R; Zhang L; Huang S; Cheng J; Liao N; Wang F; Mo L; Mo Z; Li L
    FEBS Open Bio; 2023 Apr; 13(4):736-750. PubMed ID: 36814419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
    BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
    Li H; Zhang Y; Zheng S
    Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
    Front Genet; 2021; 12():696912. PubMed ID: 34512722
    [No Abstract]   [Full Text] [Related]  

  • 19. Pan-cancer analysis of PLAU indicates its potential prognostic value and correlation with neutrophil infiltration in BLCA.
    Shi K; Zhou J; Li M; Yan W; Zhang J; Zhang X; Jiang L
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166965. PubMed ID: 38000776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
    Qiu Y; Ye W; Wang C; Zang J
    Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.